[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 28 of about 28
1. Lee TT, Everett DL, Shu HK, Jahan TM, Roach M 3rd, Speight JL, Cameron RB, Phillips TL, Chan A, Jablons DM: Radical pleurectomy/decortication and intraoperative radiotherapy followed by conformal radiation with or without chemotherapy for malignant pleural mesothelioma. J Thorac Cardiovasc Surg; 2002 Dec;124(6):1183-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radical pleurectomy/decortication and intraoperative radiotherapy followed by conformal radiation with or without chemotherapy for malignant pleural mesothelioma.
  • OBJECTIVES: We performed a retrospective review of the efficacy and morbidity of radical pleurectomy/decortication and intraoperative radiotherapy followed by external beam radiation therapy with or without chemotherapy for diffuse malignant pleural mesothelioma.
  • METHODS: A total of 32 patients with diffuse malignant pleural mesothelioma were initially evaluated between January 1995 and September 2000.
  • Two patients died postoperatively, and one patient had recurrent disease previously treated at an outside institution.
  • External beam radiation therapy was generally started 1 to 2 months after resection and delivered by means of 3-dimensional conformal radiation therapy or with inverse treatment planning intensity-modulated radiation therapy.
  • When given, chemotherapy consisted of 2 to 3 cycles of cyclophosphamide, doxorubicin (Adriamycin), and cisplatin initiated 1 to 2 months after completion of radiation.
  • RESULTS: At the time of data analysis, 5 of 26 patients were alive.
  • The median overall survival and progression-free interval from the time of the operation were 18.1 and 12.2 months, respectively.
  • CONCLUSIONS: Radical pleurectomy/decortication with aggressive radiotherapy with or without chemotherapy might offer an alternative treatment option to those who cannot tolerate extrapleural pneumonectomy.
  • [MeSH-major] Mesothelioma / therapy. Pleural Neoplasms / therapy
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Intraoperative Care. Male. Pneumonectomy. Radiotherapy, Conformal. Retrospective Studies. Survival Analysis. Time Factors

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Thorac Cardiovasc Surg. 2002 Dec;124(6):1074-7 [12447170.001]
  • (PMID = 12447185.001).
  • [ISSN] 0022-5223
  • [Journal-full-title] The Journal of thoracic and cardiovascular surgery
  • [ISO-abbreviation] J. Thorac. Cardiovasc. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


2. Baratti D, Kusamura S, Sironi A, Cabras A, Fumagalli L, Laterza B, Deraco M: Multicystic peritoneal mesothelioma treated by surgical cytoreduction and hyperthermic intra-peritoneal chemotherapy (HIPEC). In Vivo; 2008 Jan-Feb;22(1):153-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multicystic peritoneal mesothelioma treated by surgical cytoreduction and hyperthermic intra-peritoneal chemotherapy (HIPEC).
  • BACKGROUND: Multicystic peritoneal mesothelioma (MPM) is an extremely uncommon lesion with uncertain malignant potential.
  • Here, we review our experience with cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC) in the management of MPM.
  • Three patients had recurrent disease after 1, 2 and 4 previous debulkings, respectively.
  • CONCLUSION: Definitive eradication by means of cytoreduction and HIPEC seems a safe and effective therapeutic option for MPM.
  • [MeSH-major] Chemotherapy, Cancer, Regional Perfusion. Hyperthermia, Induced. Mesothelioma, Cystic / therapy. Peritoneal Neoplasms / therapy
  • [MeSH-minor] Adult. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Middle Aged. Neoplasm Recurrence, Local. Neoplasm, Residual / pathology. Neoplasm, Residual / therapy. Reoperation. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18396799.001).
  • [ISSN] 0258-851X
  • [Journal-full-title] In vivo (Athens, Greece)
  • [ISO-abbreviation] In Vivo
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


3. Ishikawa T, Wanifuchi H, Abe K, Kato K, Watanabe A, Okada Y: Brain metastasis in malignant pleural mesothelioma presenting as intratumoral hemorrhage. Neurol Med Chir (Tokyo); 2010;50(11):1027-30
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brain metastasis in malignant pleural mesothelioma presenting as intratumoral hemorrhage.
  • A 51-year-old man presented with a rare case of brain metastasis of malignant pleural mesothelioma (MPM) manifesting as intratumoral hemorrhage.
  • He had undergone several treatments such as left pneumonectomy, pleurectomy, chemotherapy with cis-diamminedichloroplatinum and gemcitabine hydrochloride, and irradiation.
  • Five years later, computed tomography revealed right parietal metastasis with intratumoral hemorrhage and the patient was treated by surgery and irradiation.
  • Six months after the surgery, recurrent intratumoral hemorrhage occurred and a second surgery was performed.
  • Intratumoral hemorrhage may occur in patients with solitary brain metastasis of MPM, so surgery should be considered as a general candidate treatment for metastatic tumors.
  • [MeSH-major] Brain Neoplasms / complications. Brain Neoplasms / secondary. Cerebral Hemorrhage / etiology. Mesothelioma / complications. Mesothelioma / secondary. Pleural Neoplasms / pathology
  • [MeSH-minor] Diagnosis, Differential. Humans. Male. Middle Aged. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21123992.001).
  • [ISSN] 1349-8029
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


Advertisement
4. Guadagni S, Clementi M, Valenti M, Fiorentini G, Cantore M, Kanavos E, Amicucci G: Thoracic stop-flow perfusion in the treatment of refractory malignant pleural mesothelioma: a phase I-II evaluation/trial. In Vivo; 2006 Nov-Dec;20(6A):715-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thoracic stop-flow perfusion in the treatment of refractory malignant pleural mesothelioma: a phase I-II evaluation/trial.
  • Malignant pleural mesothelioma (MPM) is an aggressive treatment-resistant tumor with a median survival from diagnosis of 12 months.
  • Although multimodality protocols that combine aggressive surgery and adjuvant chemotherapy or radiotherapy have shown improved survival in selected cases, the majority of patients with MPM are not suitable for radical surgery due to advanced stage and comorbid medical illness.
  • For these patients combination chemotherapy with Pemetrex and Cisplatin should be considered for first line palliative chemotherapy.
  • The therapeutic options available to patients with MPM resistant or refractory to systemic chemotherapy are very limited.
  • Thoracic "stop-flow" perfusion (TSP) is a semi-invasive loco-regional drug delivery system that, limiting the circulation to the thorax during the anticancer agent's infusion, claims the advantage of reaching high drug concentration at the tumor site while maintaining a low systemic toxicity.
  • The aim of this phase I-II study was to evaluate the toxicity profile and efficacy of two different platinum-based combined regimens--cisplatin plus mitomycin-C (MMC) and cisplatin plus melphalan (L-PAM)--administered using TSP technique in patients with advanced or recurrent MPM who had refractory disease after systemic first line chemotherapy.
  • Between January 1995 and December 2001, 27 patients were enrolled in the study and submitted to TSP using the two different chemotherapy cisplatin based regimens: 12 patients received cisplatin 100 mg/m2 plus MMC 20 mg/m2 (MMC arm) and 15 cisplatin 100 mg/m2 plus L-PAM 50 mg/m2 (L-PAM arm).
  • Objective responses were assessed by CT-scan 30 and 60 days after the end of treatment in all 27 enrolled patients.
  • No patients developed progression of the disease following the first TSP.
  • The overall median time to progression was 8.9 months (range 1-41).
  • The median survival time for all patients from the beginning of regional chemotherapy was 16.6 months, with a 1-year survival rate of 62.9%, a 2-year survival rate of 18.5%, and a 3-year survival rate of 7.4%.
  • Our data show that TSP is a relatively effective second-line treatment in patients with progressive disease after systemic chemotherapy, with a low rate of major complications and treatment-related toxicity.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Cancer, Regional Perfusion / methods. Mesothelioma / drug therapy. Pleural Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Humans. Male. Melphalan / administration & dosage. Middle Aged. Mitomycin / administration & dosage. Neoplasm Staging. Survival Rate. Tomography, X-Ray Computed


5. Kusama T, Kodaka T, Tsunemine H, Akasaka H, Koizumi N, Fujimoto K, Sakano S, Ito R, Kondo T, Kitazawa S, Yamamura H, Takahashi K: [A case of sarcomatoid malignant peritoneal mesothelioma responding to combination chemotherapy of cyclophosphamide, vincristine, adriamycin and dacarbazine(CYVADIC)]. Gan To Kagaku Ryoho; 2009 Mar;36(3):475-8
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of sarcomatoid malignant peritoneal mesothelioma responding to combination chemotherapy of cyclophosphamide, vincristine, adriamycin and dacarbazine(CYVADIC)].
  • A computed tomography(CT)revealed massive tumors in abdominal cavity.
  • By using immunohistochemical staining, the patient was diagnosed as sarcomatoid malignant peritoneal mesothelioma.
  • Rapidly abdominal fullness occurred as of 22 days after the operation, and an abdominal CT revealed the massive recurrent tumors.
  • We started a combination chemotherapy of cyclophosphamide, vincristine, adriamycin and dacarbazine (CYVADIC).
  • The recurrent tumors showed remarkable reduction after the two courses of CYVADIC chemotherapy.
  • Although we next started carboplatin and paclitaxel combination chemotherapy, she died due to rapidly progression of the disease with disseminated intravascular coagulation after 132 days of the operation.
  • Malignant mesothelioma, especially sarcomatoid mesothelioma, is known to have a poor prognosis.
  • However, our case suggests that we could improve the prognosis of sarcomatoid malignant mesothelioma by aggressive chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Mesothelioma / drug therapy. Mesothelioma / pathology. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / pathology. Sarcoma / drug therapy. Sarcoma / pathology
  • [MeSH-minor] Aged. Combined Modality Therapy. Cyclophosphamide / therapeutic use. Dacarbazine / therapeutic use. Disease Progression. Doxorubicin / therapeutic use. Fatal Outcome. Female. Humans. Tomography, X-Ray Computed. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19295275.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


6. Fennell DA, Steele JP, Shamash J, Evans MT, Wells P, Sheaff MT, Rudd RM, Stebbing J: Efficacy and safety of first- or second-line irinotecan, cisplatin, and mitomycin in mesothelioma. Cancer; 2007 Jan 1;109(1):93-9
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy and safety of first- or second-line irinotecan, cisplatin, and mitomycin in mesothelioma.
  • BACKGROUND: Malignant pleural mesothelioma (MPM) is a rapidly progressive lethal tumor.
  • Treatment options remain limited and the outcome in recurrent disease is poor.
  • METHODS: A Phase II open-label noncomparative study was conducted to assess the safety and efficacy of the triplet combination irinotecan, cisplatin, and mitomycin-C (IPM) chemotherapy in untreated patients and in those with previous exposure to chemotherapy.
  • Psychosocial well-being improved during chemotherapy and the main toxicity observed was neutropenia (40%).
  • CONCLUSIONS: IPM appeared to have a reasonable response rate with an acceptable toxicity profile in the first- and second-line treatment of MPM.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Mesothelioma / drug therapy. Pleural Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Cisplatin / administration & dosage. Clinical Trials, Phase II as Topic. Female. Humans. Male. Middle Aged. Mitomycin / administration & dosage. Quality of Life. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 American Cancer Society.
  • (PMID = 17146783.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; 7673326042 / irinotecan; Q20Q21Q62J / Cisplatin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


7. Ramalingam SS, Belani CP, Ruel C, Frankel P, Gitlitz B, Koczywas M, Espinoza-Delgado I, Gandara D: Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma. J Thorac Oncol; 2009 Jan;4(1):97-101
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma.
  • This class of compounds has demonstrated anticancer activity in malignant mesothelioma.
  • We conducted a phase II study of belinostat in patients with relapsed malignant pleural mesothelioma.
  • METHODS: Patients with advanced mesothelioma, progression with one prior chemotherapy regimen and Eastern Cooperative Oncology Group performance status 0-2 were eligible.
  • A median of two cycles of therapy were administered.
  • One patient died as a consequence of cardiac arrhythmia which was deemed 'possibly' related to therapy.
  • CONCLUSIONS: Belinostat is not active as monotherapy against recurrent malignant pleural mesothelioma.
  • Evaluation of combination strategies or alternate dosing schedules may be necessary for further development of this novel agent in mesothelioma.

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] Clin Cancer Res. 2008 Feb 1;14(3):804-10 [18245542.001]
  • [Cites] Semin Oncol. 2002 Feb;29(1):41-50 [11836668.001]
  • [Cites] Mol Cancer Ther. 2003 Feb;2(2):151-63 [12589032.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14):2636-44 [12860938.001]
  • [Cites] Mol Cancer Ther. 2003 Aug;2(8):721-8 [12939461.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Jan 30;314(1):186-91 [14715264.001]
  • [Cites] J Natl Cancer Inst. 1987 Jun;78(6):1053-60 [3473246.001]
  • [Cites] J Clin Oncol. 1988 Jan;6(1):147-53 [3335886.001]
  • [Cites] Control Clin Trials. 1989 Mar;10(1):1-10 [2702835.001]
  • [Cites] J Biol Chem. 1990 Oct 5;265(28):17174-9 [2211619.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Mar 17;95(6):3003-7 [9501205.001]
  • [Cites] Anticancer Res. 1998 May-Jun;18(3B):2063-8 [9677468.001]
  • [Cites] Clin Lung Cancer. 2006 Jan;7(4):257-61 [16512979.001]
  • [Cites] J Transl Med. 2007;5:49 [17935615.001]
  • [Cites] Invest New Drugs. 2008 Feb;26(1):81-7 [17960324.001]
  • [Cites] Int J Cancer. 2008 Mar 15;122(6):1400-10 [18027850.001]
  • [Cites] Oncogene. 2002 Jan 17;21(3):427-36 [11821955.001]
  • (PMID = 19096314.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CM / N01 CM062209; United States / NCI NIH HHS / CA / N01CM62209; United States / NCI NIH HHS / CM / N01 CM-62209
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 0 / Histone Deacetylase Inhibitors; 0 / Hydroxamic Acids; 0 / Sulfonamides; F4H96P17NZ / belinostat
  • [Other-IDs] NLM/ NIHMS107784; NLM/ PMC3263397
  •  go-up   go-down


8. Tan C, Barrington S, Rankin S, Landau D, Pilling J, Spicer J, Cane P, Lang-Lazdunski L: Role of integrated 18-fluorodeoxyglucose position emission tomography-computed tomography in patients surveillance after multimodality therapy of malignant pleural mesothelioma. J Thorac Oncol; 2010 Mar;5(3):385-8
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of integrated 18-fluorodeoxyglucose position emission tomography-computed tomography in patients surveillance after multimodality therapy of malignant pleural mesothelioma.
  • INTRODUCTION: To investigate the role of 18-fluorodeoxyglucose positron emission tomography-computed tomography (18-FDG-PET-CT) in the surveillance of patients after multimodality treatment of malignant pleural mesothelioma.
  • METHODS: Retrospective study of patients who had chemotherapy, radical surgery, extrapleural pneumonectomy or pleurectomy/decortication, and radiotherapy for mesothelioma in our unit.
  • PET-CT was performed after multimodality therapy to evaluate response to treatment or when disease recurrence was suspected.
  • Twenty-five patients had PET-CT performed after multimodality therapy.
  • This was performed in 11 patients in whom disease recurrence was suspected at a median of 9 (range, 6-16) months after treatment.
  • PET-CT correctly diagnosed recurrent disease in eight patients and missed microscopic recurrence in one.
  • Surveillance PET-CT was performed in 14 asymptomatic patients at a median of 11 (range, 7-13) months after treatment.
  • The standard uptake value max of recurrent mesothelioma was 8.9 +/- 4.0 (4-18.4).
  • CONCLUSIONS: 18-FDG-PET-CT is useful in diagnosing disease recurrence after multimodality therapy for malignant pleural mesothelioma.
  • [MeSH-major] Fluorodeoxyglucose F18. Mesothelioma / radiography. Mesothelioma / radionuclide imaging. Positron-Emission Tomography. Tomography, X-Ray Computed
  • [MeSH-minor] Aged. Antineoplastic Agents / therapeutic use. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / radiography. Neoplasm Recurrence, Local / radionuclide imaging. Neoplasm Recurrence, Local / therapy. Pleural Neoplasms / radiography. Pleural Neoplasms / radionuclide imaging. Pleural Neoplasms / therapy. Population Surveillance. Radiopharmaceuticals. Radiotherapy Dosage. Retrospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20087231.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


9. Baratti D, Kusamura S, Nonaka D, Oliva GD, Laterza B, Deraco M: Multicystic and well-differentiated papillary peritoneal mesothelioma treated by surgical cytoreduction and hyperthermic intra-peritoneal chemotherapy (HIPEC). Ann Surg Oncol; 2007 Oct;14(10):2790-7
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multicystic and well-differentiated papillary peritoneal mesothelioma treated by surgical cytoreduction and hyperthermic intra-peritoneal chemotherapy (HIPEC).
  • BACKGROUND: Multicystic peritoneal mesothelioma (MPM) and well-differentiated papillary peritoneal mesothelioma (WDPPM) are exceedingly uncommon lesions with uncertain malignant potential and no uniform treatment strategy.
  • The aim of the current study was to review our experience with cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC) in these clinical settings.
  • Seven patients had recurrent disease after previous debulking (one operation in five patients, two in one, four in one).
  • One patient underwent the procedure twice due to locoregional MPM recurrence.
  • Transition of typical WDPPM to malignant biphasic mesothelioma was documented in one patient who died of disease progression following incomplete cytoreduction and HIPEC.
  • Following multimodality treatment, 5-year overall and progression-free survival were 90.0% (standard error = 9.0) and 79.7% (11.9), respectively.
  • Definitive tumor eradication by means of cytoreduction and HIPEC seems more effective than debulking surgery in preventing disease recurrence or transition to aggressive malignancies.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Cancer, Regional Perfusion. Hyperthermia, Induced. Mesothelioma, Cystic / drug therapy. Mesothelioma, Cystic / surgery. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Combined Modality Therapy. Disease-Free Survival. Doxorubicin / administration & dosage. Female. Follow-Up Studies. Humans. Infusions, Parenteral. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Neoplasm, Residual / drug therapy. Neoplasm, Residual / mortality. Neoplasm, Residual / pathology. Neoplasm, Residual / surgery. Reoperation

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17661150.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


10. Gupta NP, Kumar R: Malignant gonadal mesothelioma. Curr Treat Options Oncol; 2002 Oct;3(5):363-7
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant gonadal mesothelioma.
  • Malignant mesothelioma of the gonads is a rare and highly lethal disease.
  • Occasionally, patients with localized disease at the time of detection have been known to survive for more than 10 years; however, the majority will not live beyond 5 years, with median survival being approximately 23 months.
  • The principle reasons for this are difficulty in making a preoperative diagnosis and advanced stage at the time of treatment.
  • Adjuvant therapy in the form of chemotherapy, immunotherapy, or radiotherapy has negligible benefit.
  • For advanced or recurrent disease, we suggest local radical resection with chemotherapy, including high-dose cisplatin and doxorubicin for two cycles of 5 days each; add local radiotherapy for uncontrolled locally advanced disease.
  • [MeSH-major] Genital Neoplasms, Male / drug therapy. Genital Neoplasms, Male / surgery. Mesothelioma / drug therapy. Mesothelioma / surgery

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Urol. 1990 Dec;144(6):1475-8 [2146405.001]
  • [Cites] Minerva Urol Nefrol. 2000 Mar;52(1):33-5 [11517828.001]
  • [Cites] Surg Today. 1999;29(10):1106-10 [10554340.001]
  • [Cites] Semin Diagn Pathol. 2000 Nov;17(4):294-306 [11202546.001]
  • [Cites] Br J Radiol. 1999 May;72(857):502-4 [10505018.001]
  • [Cites] Zentralbl Chir. 2001 Mar;126(3):229-32 [11301890.001]
  • [Cites] Cancer. 1998 Dec 15;83(12):2437-46 [9874447.001]
  • [Cites] Br J Urol. 1995 May;75(5):679-80 [7613813.001]
  • [Cites] Histopathology. 2000 Aug;37(2):150-9 [10931239.001]
  • [Cites] Jpn J Clin Oncol. 1991 Oct;21(5):377-83 [1753419.001]
  • [Cites] J Surg Oncol. 1999 Apr;70(4):251-4 [10219022.001]
  • [Cites] Ann Intern Med. 1984 Jan;100(1):19-24 [6197916.001]
  • [Cites] Am J Surg Pathol. 1995 Jul;19(7):815-25 [7793480.001]
  • [Cites] Urol Int. 1995;55(4):215-7 [8588269.001]
  • (PMID = 12194801.001).
  • [ISSN] 1527-2729
  • [Journal-full-title] Current treatment options in oncology
  • [ISO-abbreviation] Curr Treat Options Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 15
  •  go-up   go-down


11. de Bree E, van Ruth S, Baas P, Rutgers EJ, van Zandwijk N, Witkamp AJ, Zoetmulder FA: Cytoreductive surgery and intraoperative hyperthermic intrathoracic chemotherapy in patients with malignant pleural mesothelioma or pleural metastases of thymoma. Chest; 2002 Feb;121(2):480-7
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytoreductive surgery and intraoperative hyperthermic intrathoracic chemotherapy in patients with malignant pleural mesothelioma or pleural metastases of thymoma.
  • STUDY OBJECTIVES: No established curative treatment is available for pleural thymoma metastases and malignant pleural mesothelioma (MPM).
  • Recently, peritoneal malignancies have been treated by cytoreductive surgery and intraoperative hyperthermic intracavitary perfusion chemotherapy (HIPEC).
  • We investigated the feasibility and safety of this multimodality treatment in the thoracic cavity.
  • PATIENTS: Three patients with pleural thymoma metastases and 11 patients with pleural mesothelioma were treated.
  • INTERVENTIONS: Cytoreductive surgery and intraoperative hyperthermic intrathoracic perfusion chemotherapy (HITHOC) with cisplatin and adriamycin were performed.
  • The mesothelioma patients received adjuvant radiotherapy on the thoracotomy wound and drainage tracts.
  • Severe chemotherapy-related complications were not observed.
  • A solitary mediastinal and a contralateral pleural thymoma recurrence were successfully treated by radiotherapy and a contralateral HITHOC procedure.
  • After a mean follow-up period of 7.4 months, nine mesothelioma patients are alive.
  • Two mesothelioma patients died of contralateral pleural and peritoneal recurrent disease, while one patient is alive with locoregional recurrence.
  • [MeSH-major] Mesothelioma / therapy. Pleural Neoplasms / secondary. Pleural Neoplasms / therapy. Thymoma / secondary. Thymoma / therapy. Thymus Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Cisplatin / administration & dosage. Combined Modality Therapy. Doxorubicin / administration & dosage. Feasibility Studies. Female. Follow-Up Studies. Humans. Male. Middle Aged. Survival Rate


12. Hayashi H, Okamoto I, Ichikawa Y, Miyazaki M, Yoshioka H, Kunimasa K, Nakagawa K: Retreatment of recurrent malignant pleural mesothelioma with cisplatin and pemetrexed. Int J Clin Oncol; 2010 Oct;15(5):497-9
Hazardous Substances Data Bank. GUANINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retreatment of recurrent malignant pleural mesothelioma with cisplatin and pemetrexed.
  • Combination chemotherapy with cisplatin and pemetrexed is the most active first-line regimen for malignant pleural mesothelioma (MPM).
  • However, no drugs have been approved for second-line treatment of MPM, with effective regimens remaining to be identified for patients in relapse.
  • We have now evaluated the combination of cisplatin and pemetrexed for retreatment of patients with recurrent MPM.
  • Four men with MPM, all of whom received initial treatment with cisplatin and pemetrexed, underwent retreatment with this drug combination.
  • Two of the patients achieved an objective response to the first-line chemotherapy with no evidence of disease progression for 6.4 or 11.4 months, respectively.
  • The two patients who showed an objective response to first-line chemotherapy showed a partial response to retreatment, with a time to progression of 5.0 or 8.2 months, whereas the other two patients had progressive disease with a time to progression of 1.0 or 1.4 months, respectively.
  • Retreatment with cisplatin and pemetrexed is a potential therapeutic option for certain patients with recurrent epithelioid MPM, possibly including those who show tumor regression with a time to progression of 6 months or more after the initial chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Mesothelioma / drug therapy. Neoplasm Recurrence, Local / drug therapy. Pleural Neoplasms / drug therapy
  • [MeSH-minor] Aged. Cisplatin / administration & dosage. Glutamates / administration & dosage. Guanine / administration & dosage. Guanine / analogs & derivatives. Humans. Male. Middle Aged. Pemetrexed. Time Factors. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • Hazardous Substances Data Bank. PEMETREXED .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lung Cancer. 2008 May;60(2):294-7 [17919769.001]
  • [Cites] Ann Oncol. 2005 Jun;16(6):923-7 [15824080.001]
  • [Cites] Semin Oncol. 2006 Apr;33(2 Suppl 6):S12-6 [16716798.001]
  • [Cites] Ann Oncol. 2004 Feb;15(2):257-60 [14760119.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14):2636-44 [12860938.001]
  • (PMID = 20224880.001).
  • [ISSN] 1437-7772
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Glutamates; 04Q9AIZ7NO / Pemetrexed; 5Z93L87A1R / Guanine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


13. Budde LS, Hanna NH: Pemetrexed (Alimta): improving outcomes in malignant pleural mesothelioma. Expert Rev Anticancer Ther; 2004 Jun;4(3):361-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pemetrexed (Alimta): improving outcomes in malignant pleural mesothelioma.
  • During the past four decades, chemotherapy has failed to demonstrate a consistent clinical benefit for patients with unresectable or recurrent malignant pleural mesothelioma (MPM).
  • Consequently, there has been no standard chemotherapy nor US Food and Drug Administration (FDA)-approved drug for patients with this disease.
  • The introduction of pemetrexed (Alimta, Eli Lilly), a multitargeted antifolate agent, has improved the outlook for patients with mesothelioma by demonstrating a positive impact on quality of life and by prolonging survival.
  • Pemetrexed is the first FDA-approved drug for the treatment of MPM.
  • The combination of cisplatin plus pemetrexed is now the standard of care for the treatment of the disease.
  • This article summarizes historical chemotherapy trials in MPM; discusses key features of clinical trial design for MPM; summarizes the results of a landmark Phase III trial of pemetrexed and cisplatin in MPM; discusses the relative contributions of pemetrexed and cisplatin to the regimen; explains the importance of vitamin supplementation of pemetrexed; and provides direction for future clinical trials in this disease.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Enzyme Inhibitors / therapeutic use. Glutamates / therapeutic use. Guanine / analogs & derivatives. Guanine / therapeutic use. Mesothelioma / drug therapy. Pleural Neoplasms / drug therapy. Thymidylate Synthase / antagonists & inhibitors

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • Hazardous Substances Data Bank. PEMETREXED .
  • Hazardous Substances Data Bank. GUANINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15161435.001).
  • [ISSN] 1473-7140
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Enzyme Inhibitors; 0 / Glutamates; 04Q9AIZ7NO / Pemetrexed; 5Z93L87A1R / Guanine; EC 2.1.1.45 / Thymidylate Synthase
  • [Number-of-references] 47
  •  go-up   go-down


14. Molina Garrido MJ, Mora Rufete A, Rodríguez-Lescure A, Cascón Pérez JD, Ardoy F, Guillén Ponce C, Carrato Mena A: Recurrent pericardial effusion as initial manifestation of primary diffuse pericardial malignant mesothelioma. Clin Transl Oncol; 2006 Sep;8(9):694-6
MedlinePlus Health Information. consumer health - Pericardial Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent pericardial effusion as initial manifestation of primary diffuse pericardial malignant mesothelioma.
  • The case of a 61-year-old woman who presented a recurrent symptomatic pericardial effusion and a malignant cardiac tamponade six months prior to the detection of a mediastinal anterior mass is described.
  • Diffuse malignant pericardial mesothelioma was diagnosed after mediastinal mass biopsy.
  • The patient underwent further oncological evaluation followed by chemotherapy.
  • [MeSH-major] Heart Neoplasms / diagnosis. Mesothelioma / diagnosis. Pericardial Effusion / etiology. Pericardium

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cardiovasc Clin. 1973;5(1):207-38 [4589961.001]
  • [Cites] Am Heart J. 1988 Jun;115(6):1321-2 [3376853.001]
  • [Cites] Med Pediatr Oncol. 1995 Mar;24(3):208-12 [7838044.001]
  • [Cites] J Cardiovasc Surg (Torino). 1994 Jun;35(3):261-7 [8040178.001]
  • [Cites] Cardiovasc Clin. 1976;7(3):257-69 [1000541.001]
  • [Cites] Am J Cardiol. 1979 Nov;44(6):1110-4 [495505.001]
  • [Cites] Pathol Int. 1995 Aug;45(8):622-5 [7496510.001]
  • [Cites] Am Heart J. 1987 Mar;113(3):785-90 [3548297.001]
  • [Cites] Am Heart J. 1986 May;111(5):986-8 [3706117.001]
  • [Cites] Br J Dis Chest. 1983 Oct;77(4):321-43 [6357260.001]
  • (PMID = 17005474.001).
  • [ISSN] 1699-048X
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


15. Horita K, Inase N, Miyake S, Formby B, Toyoda H, Yoshizawa Y: Progesterone induces apoptosis in malignant mesothelioma cells. Anticancer Res; 2001 Nov-Dec;21(6A):3871-4
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Progesterone induces apoptosis in malignant mesothelioma cells.
  • Progesterone has been used in the treatment of patients with recurrent or metastatic progesterone receptor-positive endometrial carcinoma and breast cancer.
  • Therefore, we investigated the effect of progesterone administration on the proliferation and apoptosis in a mesothelioma cell line, 211H.
  • These results clearly demonstrated that progesterone administration suppressed the cell proliferation and induced apoptosis in malignant mesothelioma cells.
  • [MeSH-major] Apoptosis / drug effects. Mesothelioma / drug therapy. Mesothelioma / pathology. Progesterone / pharmacology
  • [MeSH-minor] Breast Neoplasms / drug therapy. Breast Neoplasms / metabolism. Breast Neoplasms / pathology. Cell Division / drug effects. DNA Fragmentation / drug effects. Humans. In Situ Nick-End Labeling. Receptors, Progesterone / biosynthesis. Reverse Transcriptase Polymerase Chain Reaction. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • Hazardous Substances Data Bank. PROGESTERONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11911261.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Receptors, Progesterone; 4G7DS2Q64Y / Progesterone
  •  go-up   go-down


16. Katayam N, Tokuda A, Nakatsumi Y, Oribe Y, Fujimura M: [A case of malignant mesothelioma presenting with recurrent pneumothorax]. Nihon Kokyuki Gakkai Zasshi; 2006 Nov;44(11):807-11
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of malignant mesothelioma presenting with recurrent pneumothorax].
  • Although pneumothorax was treated successfully, increased pleural effusion, pleural thickening and subcutaneal tumor at the thoracic drainage suture site developed.
  • The histological examination of the biopsied subcutaneous tumor showed mixed type malignant pleural mesothelioma.
  • Chemotherapy with gemcitabine and vinorelbine could not control the progression.
  • [MeSH-major] Mesothelioma / diagnosis. Pleural Neoplasms / diagnosis. Pneumothorax / etiology
  • [MeSH-minor] Aged. Antineoplastic Agents / therapeutic use. Disease Progression. Fatal Outcome. Humans. Male. Picibanil / therapeutic use. Recurrence

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Collapsed Lung.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17144577.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 39325-01-4 / Picibanil
  •  go-up   go-down


17. Watanabe S, Shimokawa S, Sakasegawa K, Nakamura Y, Sakata R: [Surgical treatment for malignant pleural mesothelioma in eight cases]. Kyobu Geka; 2000 Dec;53(13):1101-4
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical treatment for malignant pleural mesothelioma in eight cases].
  • Between 1987 and March 2000, we have operated on eight patients for malignant mesothelioma which consisted of four of localized type and four of diffuse type.
  • We have aggressively resected mesothelioma combined with chemotherapy whether the tumor was primary or recurrent, and concluded the following.
  • 1) In localized malignant mesothelioma, en-bloc primary tumor resection was possible and additional resection for recurrence was effective and useful for long time survival.
  • 2) In diffuse malignant mesothelioma, complete tumor resection was impossible to even perform pleuropneumonectomy accompanied with partial resection of pericardium and diaphragm and, therefore, the prognosis was poor in four patients and all died around one year.
  • 3) Because recurrent pattern for localized type was diffuse type, diagnosis and surgical treatment in early stage was essential for long time survival.
  • [MeSH-major] Mesothelioma / surgery. Pleural Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Diaphragm / surgery. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / surgery. Pericardium / surgery. Pleura / surgery. Pneumonectomy. Prognosis

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11127555.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


18. Baratti D, Vaira M, Kusamura S, D'Amico S, Balestra MR, Cioppa T, Mingrone E, De Simone M, Deraco M: Multicystic peritoneal mesothelioma: outcomes and patho-biological features in a multi-institutional series treated by cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC). Eur J Surg Oncol; 2010 Nov;36(11):1047-53
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multicystic peritoneal mesothelioma: outcomes and patho-biological features in a multi-institutional series treated by cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC).
  • AIM: This retrospective multi-institutional study addresses the role of surgical cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of multicystic peritoneal mesothelioma (MCPM).
  • MCPM is an uncommon tumour with uncertain malignant potential and no current standard therapy.
  • Nine patients had recurrent disease after previous debulking (one operation in six patients, two in two, four in one).
  • Biological markers related to mesothelioma origin and clinical features were assessed by immunohistochemical studies.
  • All the patients are presently alive with no evidence of disease, including two patients who underwent the procedure twice, due to locoregional disease recurrence.
  • Definitive tumour eradication by means of cytoreduction and HIPEC seems more effective than debulking surgery in preventing disease relapse.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Chemotherapy, Cancer, Regional Perfusion / methods. Hyperthermia, Induced. Mesothelioma / pathology. Mesothelioma / therapy. Peritoneal Neoplasms / pathology. Peritoneal Neoplasms / therapy
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant / methods. Disease-Free Survival. Female. Humans. Infusions, Parenteral. Kaplan-Meier Estimate. Length of Stay. Male. Middle Aged. Neoplasm, Residual / pathology. Patient Selection. Prognosis. Retrospective Studies. Surgical Procedures, Operative / methods. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20832234.001).
  • [ISSN] 1532-2157
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


19. Buchholz BM, Gütgemann I, Fischer HP, Gorschlüter M, Türler A, Kalff JC, Hirner A, Standop J: Lymph node dissection in primary intrahepatic malignant mesothelioma: case report and implications for diagnosis and therapy. Langenbecks Arch Surg; 2009 Nov;394(6):1123-30
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymph node dissection in primary intrahepatic malignant mesothelioma: case report and implications for diagnosis and therapy.
  • INTRODUCTION: In this rare case of intrahepatic malignant mesothelioma with subsequent lymph node metastases, hepatic segmentectomy in combination with repeated lymphadenectomy resulted in prolonged survival, currently 37 months after initial diagnosis.
  • DISCUSSION: Immunohistochemically, vascular endothelial growth factor receptor-1 expressing tumor cells were surrounded by a dense D 2-40-positive lymphangiovascular network, suggesting tumor induced lymphangiogenesis correlating to 2-deoxy-2[(18)F]fluoro-d-glucose-positron emission tomography/computed tomography-positive recurrent intraabdominal and intrathoracic lymphatic tumor spread.
  • Therefore, extended lymphadenectomy during primary tumor resection and combined adjuvant chemotherapy with promising anticancer agents possessing antilymphangiogenic and antimetabolite properties should be considered to prolong survival in cases of extrathoracic malignant mesothelioma.
  • [MeSH-major] Hepatectomy. Liver Neoplasms / pathology. Liver Neoplasms / surgery. Lymph Node Excision. Mesothelioma / secondary. Mesothelioma / surgery

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Med Chem. 1992 Nov 13;35(23):4450-4 [1447744.001]
  • [Cites] Semin Oncol. 2005 Jun;32(3):336-50 [15988688.001]
  • [Cites] N Engl J Med. 2004 Jun 3;350(23 ):2335-42 [15175435.001]
  • [Cites] Chir Ital. 2002 Nov-Dec;54(6):897-902 [12613343.001]
  • [Cites] Leukemia. 2004 Jun;18(6):1054-8 [15057248.001]
  • [Cites] J Thorac Oncol. 2006 Feb;1(2):169-71 [17409848.001]
  • [Cites] Clin Cancer Res. 2000 Jun;6(6):2431-9 [10873096.001]
  • [Cites] Eur J Radiol. 2007 Dec;64(3):356-66 [17954021.001]
  • [Cites] J Clin Oncol. 2006 Oct 1;24(28):4587-93 [17008700.001]
  • [Cites] Am J Pathol. 2001 Sep;159(3):893-903 [11549582.001]
  • [Cites] J Investig Dermatol Symp Proc. 2000 Dec;5(1):14-9 [11147669.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2008 Apr;28(4):658-64 [18174461.001]
  • [Cites] Magn Reson Imaging. 2003 Nov;21(9):1091-3 [14684216.001]
  • [Cites] Virchows Arch. 2006 May;448(5):655-8 [16541281.001]
  • [Cites] Blood. 2007 Feb 1;109(3):1010-7 [17032920.001]
  • [Cites] Urology. 1982 Sep;20(3):316-9 [7123728.001]
  • [Cites] Pathol Int. 1996 May;46(5):389-91 [8809888.001]
  • [Cites] Gastrointest Radiol. 1992 Spring;17 (2):129-31 [1551507.001]
  • [Cites] Zentralbl Chir. 1996;121(7):587-90 [8967200.001]
  • [Cites] Am J Surg Pathol. 2000 Sep;24(9):1183-200 [10976692.001]
  • [Cites] Nat Clin Pract Oncol. 2007 Jun;4(6):344-52 [17534390.001]
  • [Cites] APMIS. 2002 Nov;110(11):789-94 [12588419.001]
  • [Cites] Cancer Cell. 2005 Feb;7(2):121-7 [15710325.001]
  • [Cites] J Thorac Imaging. 2006 May;21(2):146-53 [16770231.001]
  • [Cites] Nat Med. 2001 Feb;7(2):186-91 [11175849.001]
  • [Cites] J Clin Invest. 2004 Apr;113(7):1040-50 [15057311.001]
  • [Cites] Cancer Res. 1970 May;30(5):1287-308 [4316726.001]
  • [Cites] Br J Cancer. 1999 Sep;81(1):54-61 [10487612.001]
  • [Cites] Clin Cancer Res. 2007 Oct 1;13(19):5918-25 [17908988.001]
  • [Cites] Nat Med. 2001 Feb;7(2):151-2 [11175837.001]
  • [Cites] Mod Pathol. 2008 Mar;21(3):256-64 [18192971.001]
  • [Cites] Cancer Res. 1997 Mar 15;57(6):1116-23 [9067281.001]
  • [Cites] J Urol. 2002 Feb;167(2 Pt 1):645-6 [11792939.001]
  • [Cites] Int J Surg Pathol. 2004 Jan;12(1):87-91 [14765281.001]
  • [Cites] N Engl J Med. 2006 Dec 14;355(24):2542-50 [17167137.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14):2636-44 [12860938.001]
  • (PMID = 19280219.001).
  • [ISSN] 1435-2451
  • [Journal-full-title] Langenbeck's archives of surgery
  • [ISO-abbreviation] Langenbecks Arch Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


20. Opitz I, Lardinois D, Arni S, Hillinger S, Vogt P, Odermatt B, Rousson V, Weder W: Local recurrence model of malignant pleural mesothelioma for investigation of intrapleural treatment. Eur J Cardiothorac Surg; 2007 May;31(5):773-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Local recurrence model of malignant pleural mesothelioma for investigation of intrapleural treatment.
  • OBJECTIVE: Local recurrence remains a major problem in the treatment of malignant pleural mesothelioma.
  • The aim of the underlying study was to establish a standardised local recurrence model in rats which enables to study different intrapleural therapies.
  • MATERIALS AND METHODS: Fifty microlitre containing 1 x 10(6) cells of a syngeneic rat malignant mesothelioma cell line (II-45), established from mesothelioma in Fischer 344 rats exposed to asbestos, were inoculated subpleurally via a left-sided thoracotomy.
  • The recurrent nodule was histopathologically confirmed.
  • In a second experiment, this new recurrence model was evaluated for the effect of intrapleural therapy with different agents: 4 ml of cisplatin-solution (100mg(2)/kg BW), cisplatin combined with the fibrin-based sealant Vivostat, 4 ml taurolidine 2%, repeated injection of 1 microg of the chemokine CCL-19 at the tumour site and 4 ml povidone-iodine in a dilution 1:10.
  • CONCLUSIONS: With this new recurrence model for investigation of malignant pleural mesothelioma in rats, we were able to investigate new intrapleural therapies after pneumonectomy.
  • [MeSH-major] Disease Models, Animal. Mesothelioma / drug therapy. Neoplasm Recurrence, Local / drug therapy. Pleural Neoplasms / drug therapy
  • [MeSH-minor] Animals. Anti-Infective Agents, Local / therapeutic use. Antineoplastic Agents / therapeutic use. Cell Line, Tumor. Chemokine CCL19. Chemokines, CC / therapeutic use. Cisplatin / therapeutic use. Combined Modality Therapy / methods. Fibrin Tissue Adhesive / therapeutic use. Male. Pneumonectomy / methods. Povidone-Iodine / therapeutic use. Rats. Rats, Inbred F344. Taurine / analogs & derivatives. Taurine / therapeutic use. Thiadiazines / therapeutic use

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • Hazardous Substances Data Bank. Taurine .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. Povidone-iodine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17350855.001).
  • [ISSN] 1010-7940
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anti-Infective Agents, Local; 0 / Antineoplastic Agents; 0 / Chemokine CCL19; 0 / Chemokines, CC; 0 / Fibrin Tissue Adhesive; 0 / Thiadiazines; 1EQV5MLY3D / Taurine; 25655-41-8 / Povidone-Iodine; 8OBZ1M4V3V / taurolidine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


21. Higashiyama M, Oda K, Okami J, Maeda J, Kodama K, Takami K, Morinaga K, Takano T, Kobayashi H: In vitro-chemosensitivity test using the collagen gel droplet embedded culture drug test (CD-DST) for malignant pleural mesothelioma: possibility of clinical application. Ann Thorac Cardiovasc Surg; 2008 Dec;14(6):355-62
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vitro-chemosensitivity test using the collagen gel droplet embedded culture drug test (CD-DST) for malignant pleural mesothelioma: possibility of clinical application.
  • PURPOSE: An in vitro-chemosensitivity test using the collagen gel droplet embedded culture drug test (CD-DST), established by Kobayashi et al. (Jpn J Cancer Res 2001; 92: 203-10), has been widely used on various tumors.
  • This study retrospectively evaluated its possibility of clinical application to patients with malignant pleural mesothelioma (MPM).
  • Correlations between CD-DST data and clinical effects were then assessed for some MPM patients undergoing chemotherapy.
  • No difference was observed between CD-DST data of each chemoagent and histological type.
  • Of these MPM patients, 14 clinical effects on 13 patients who underwent chemotherapy for primary or recurrent disease were reviewed in comparison with CD-DST data of each chemoagent.
  • CD-DST data for the chemoagents were to a limited extent significantly correlated with the disease control status of chemotherapy (p=0.052).
  • CONCLUSION: Although the number of tested MPM specimens was small, CD-DST data obtained by biopsy or surgical-fresh specimens of MPM marginally correlated to the disease control effect of chemotherapy for this disease.
  • Therefore CD-DST may possibly be applied to selecting the chemotherapy regimen for MPM.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Cell Proliferation / drug effects. Collagen. Drug Resistance, Neoplasm. Gels. Mesothelioma / drug therapy. Pleural Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy. Drug Screening Assays, Antitumor. Female. Humans. Male. Middle Aged. Patient Selection. Predictive Value of Tests. Retrospective Studies. Sensitivity and Specificity. Tissue Culture Techniques. Treatment Outcome. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19131921.001).
  • [ISSN] 2186-1005
  • [Journal-full-title] Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia
  • [ISO-abbreviation] Ann Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Gels; 9007-34-5 / Collagen
  •  go-up   go-down


22. Balli A, Lachat M, Gerber B, Baumgartner C, Glaus T: [Cardiac tamponade due to pericardial mesothelioma in an 11-year-old dog: diagnosis, medical and interventional treatments]. Schweiz Arch Tierheilkd; 2003 Feb;145(2):82-7
MedlinePlus Health Information. consumer health - Pericardial Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cardiac tamponade due to pericardial mesothelioma in an 11-year-old dog: diagnosis, medical and interventional treatments].
  • After partial pericardectomy by thoracoscopy and after obtaining a histological diagnosis of mesothelioma adjuvant intracavitary chemotherapy using cisplatin was performed.
  • Already one week later the dog developed marked dyspnea due to severe pleural effusion.
  • Despite extensive treatments life span from initial presentation to euthanasia was only 5 months.
  • Necropsy revealed extensive mesothelioma metastases covering the whole pleura, epicardium and remaining pericardium.
  • Diagnostic and therapeutic aspects of (recurrent) pericardial effusion are discussed based on this case.
  • [MeSH-major] Cardiac Tamponade / veterinary. Dog Diseases / diagnosis. Heart Neoplasms / veterinary. Mesothelioma / veterinary
  • [MeSH-minor] Animals. Diagnosis, Differential. Dogs. Euthanasia, Animal. Fatal Outcome. Male. Pericardial Effusion / etiology. Pericardial Effusion / therapy. Pericardial Effusion / veterinary. Pericardiectomy / veterinary. Pericardiocentesis / veterinary. Pleural Effusion, Malignant / etiology. Pleural Effusion, Malignant / therapy. Pleural Effusion, Malignant / veterinary. Recurrence

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12649954.001).
  • [ISSN] 0036-7281
  • [Journal-full-title] Schweizer Archiv für Tierheilkunde
  • [ISO-abbreviation] Schweiz. Arch. Tierheilkd.
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  •  go-up   go-down


23. Villela LR, Stanford BL, Shah SR: Pemetrexed, a novel antifolate therapeutic alternative for cancer chemotherapy. Pharmacotherapy; 2006 May;26(5):641-54
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pemetrexed, a novel antifolate therapeutic alternative for cancer chemotherapy.
  • Pemetrexed is a newly approved antifolate agent for the treatment of malignant pleural mesothelioma (MPM) and metastatic non-small cell lung cancer (NSCLC).
  • The pharmacokinetics and pharmacodynamics of pemetrexed are described to provide a better understanding of the properties of this drug.
  • Therapeutic uses are assessed, beginning with the approved indications of MPM and NSCLC.
  • However, pemetrexed has been studied in numerous phase II trials for other types of solid malignancies, and completed trials are reviewed.
  • Data on adverse effects and drug interactions are also provided.
  • Pemetrexed should be used as a standard of care for unresectable MPM and recurrent metastatic NSCLC.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Folic Acid Antagonists / therapeutic use. Glutamates / therapeutic use. Guanine / analogs & derivatives. Neoplasms / drug therapy
  • [MeSH-minor] Animals. Clinical Trials, Phase II as Topic. Drug Interactions. Humans. Pemetrexed

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. PEMETREXED .
  • Hazardous Substances Data Bank. GUANINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16637794.001).
  • [ISSN] 0277-0008
  • [Journal-full-title] Pharmacotherapy
  • [ISO-abbreviation] Pharmacotherapy
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Folic Acid Antagonists; 0 / Glutamates; 04Q9AIZ7NO / Pemetrexed; 5Z93L87A1R / Guanine
  • [Number-of-references] 62
  •  go-up   go-down


24. Kolschmann S, Ballin A, Gillissen A: Clinical efficacy and safety of thoracoscopic talc pleurodesis in malignant pleural effusions. Chest; 2005 Sep;128(3):1431-5
Hazardous Substances Data Bank. TALC .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical efficacy and safety of thoracoscopic talc pleurodesis in malignant pleural effusions.
  • STUDY OBJECTIVES: In patients with disseminated neoplastic disease, recurrent pleural effusion is frequently observed.
  • The purpose of this study was to determine the long-term efficacy and safety of pleurodesis by thoracoscopic talc poudrage (TTP) in malignant pleural effusions (MPEs).
  • METHODS: We report a consecutive series of 102 patients (45 women, 57 men; 20 to 83 years of age) who underwent medical thoracoscopy and TTP for recurrent MPE between 1999 and 2001.
  • One hundred eighty-day follow-up was completed for all patients, and outcome measures included time to recurrence of the effusion and survival.
  • Procedure-related complications were documented.
  • RESULTS: The most common primary neoplasms were lung cancer (n = 48), breast cancer (n = 16), and malignant pleural mesothelioma (n = 10).
  • Twenty-eight patients had other types of tumors, including renal cell carcinoma, ovarian carcinoma, GI tumors, prostate, malignant lymphoma, and unknown primary cancer.
  • Type of primary neoplasm had no significant influence on success rate.
  • Survival curves after 180 days showed significant differences, with best survival in mesothelioma and shortest life expectancy in lung cancer (p = 0.005).
  • Adverse effects included empyema in one case and malignant invasion of the scar.
  • CONCLUSION: Thoracoscopic talc pleurodesis is a safe and effective method to stop recurrent MPEs.
  • [MeSH-major] Irritants / administration & dosage. Pleural Effusion, Malignant / drug therapy. Pleurodesis / methods. Talc / administration & dosage. Thoracoscopy / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16162739.001).
  • [ISSN] 0012-3692
  • [Journal-full-title] Chest
  • [ISO-abbreviation] Chest
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Irritants; 14807-96-6 / Talc
  •  go-up   go-down


25. Terada T: Primary small cell carcinoma of the pleura: a case report with immunohistochemical and molecular genetic analyses of KIT and PDGFRA genes. Med Oncol; 2010 Dec;27(4):1119-22
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The patient was treated with chemotherapy and radiation and followed up in our hospital.
  • Eight years after the orchiectomy, the patient (75 years old) developed left pleural tumor and pleural effusion, and a biopsy was performed.
  • The biopsy revealed a medullary malignant tumor consisting of small round and spindle cells.
  • The following three possibilities were considered: recurrent lymphoma, mesothelioma, and small cell carcinoma.
  • The patient was treated with chemotherapy (cisplatin) and radiation (50 Gray).
  • [MeSH-minor] Aged. Humans. Immunoenzyme Techniques. Lymphoma, Large B-Cell, Diffuse / metabolism. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, Large B-Cell, Diffuse / therapy. Male. Mutation / genetics. Orchiectomy. Testicular Neoplasms / metabolism. Testicular Neoplasms / pathology. Testicular Neoplasms / surgery

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Gastroenterol. 2008 Dec 21;14(47):7256-9 [19084944.001]
  • [Cites] J Clin Oncol. 2005 Jan 1;23(1):49-57 [15545668.001]
  • [Cites] Med Oncol. 2009;26(2):247-50 [18989797.001]
  • [Cites] Histopathology. 2005 Nov;47(5):517-22 [16242000.001]
  • [Cites] Lung Cancer. 2002 Jan;35(1):91-4 [11750718.001]
  • [Cites] Hum Pathol. 2002 Dec;33(12):1182-7 [12514786.001]
  • [Cites] Pathol Int. 2002 Nov;52(11):740-6 [12685552.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2007 Dec;15(4):401-6 [18091382.001]
  • [Cites] Int J Gynecol Pathol. 2009 Jan;28(1):29-34 [19047911.001]
  • [Cites] Pathology. 2010 Jan;42(1):101-2 [20025496.001]
  • [Cites] Mod Pathol. 2003 Oct;16(10):1041-7 [14559988.001]
  • [Cites] Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):4101-8 [15217946.001]
  • [Cites] Eur J Cancer. 2003 Apr;39(6):793-9 [12651205.001]
  • [Cites] Clin Cancer Res. 2003 Jan;9(1):188-94 [12538468.001]
  • [Cites] Science. 1998 Jan 23;279(5350):577-80 [9438854.001]
  • [Cites] Arch Pathol Lab Med. 2006 Oct;130(10):1466-78 [17090188.001]
  • [Cites] Lung Cancer. 1996 Dec;16(1):87-94 [9017588.001]
  • [Cites] Semin Diagn Pathol. 2006 May;23(2):91-102 [17193822.001]
  • [Cites] Med Oncol. 2009;26(2):233-7 [18777214.001]
  • [Cites] Lung Cancer. 2007 Jun;56(3):405-13 [17420067.001]
  • [Cites] South Med J. 1989 Nov;82(11):1437-8 [2554511.001]
  • [Cites] Lung Cancer. 2006 Jun;52(3):343-7 [16574270.001]
  • [Cites] Pathol Int. 2006 Jan;56(1):1-9 [16398673.001]
  • [Cites] Pathol Int. 2009 Apr;59(4):247-50 [19351368.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2005 Sep;13(3):205-20 [16082245.001]
  • [Cites] Gastroenterology. 2003 Sep;125(3):660-7 [12949711.001]
  • [Cites] Tohoku J Exp Med. 2005 Jul;206(3):271-5 [15942157.001]
  • (PMID = 19859843.001).
  • [ISSN] 1559-131X
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Proto-Oncogene Proteins c-kit; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor alpha
  •  go-up   go-down


26. Marcy PY, Magné N, Bentolila F, Drouillard J, Bruneton JN, Descamps B: Superior vena cava obstruction: is stenting necessary? Support Care Cancer; 2001 Mar;9(2):103-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • No therapy is currently available for patients with recurrent vascular obstruction of the superior vena cava (SVC) caused by tumor regrowth after chemotherapy or radiation therapy.
  • Intravascular stenting is a new option for the treatment of vena cava syndrome.
  • Forty cancer patients with SVC syndrome (SVCS) were evaluated by computed tomography (CT) and venography.
  • The etiology was malignant in all but 2 cases: non-small-cell lung carcinoma (n = 28), mediastinal nodal metastasis (n = 5), lymphoma (n = 2), pleural mesothelioma (n = 2), small-cell lung carcinoma (n = 1), and postradiation fibrous mediastinitis (n = 2).
  • [MeSH-major] Stents. Superior Vena Cava Syndrome / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11305067.001).
  • [ISSN] 0941-4355
  • [Journal-full-title] Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
  • [ISO-abbreviation] Support Care Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


27. Pearce HL, Alice Miller M: The evolution of cancer research and drug discovery at Lilly Research Laboratories. Adv Enzyme Regul; 2005;45:229-55
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The evolution of cancer research and drug discovery at Lilly Research Laboratories.
  • This review highlights the discovery and development of chemotherapy at Eli Lilly & Company over the past 30 years from the Vinca alkaloids-vincristine, vinblastine, and vindesine-to targeted therapy.
  • Two such agents, gemcitabine and pemetrexed, underwent clinical development and are now among Lilly's portfolio of approved anticancer drugs.
  • Gemcitabine, a pyrimidine nucleoside that has a profound effect on DNA synthesis, has been approved for the treatment of pancreatic, non-small cell lung, bladder, and most recently, breast, and ovarian cancer.
  • Pemetrexed, given in combination with cisplatin, has been recently approved for the treatment of malignant pleural mesothelioma and as second-line treatment for non-small cell lung cancer.
  • Spurred by advances in the understanding of cancer as a disease process, Lilly's anticancer drug program began to transition to a more "targeted" approach during the 1990s.
  • Enzastaurin has shown promising single-agent activity in patients with relapsed diffuse large B-cell lymphoma and recurrent glioblastoma multiforme, and is an excellent candidate for combination with cytotoxic agents.
  • [MeSH-major] Antineoplastic Agents / history. Drug Industry / history. Neoplasms / history
  • [MeSH-minor] Clinical Trials as Topic. Deoxycytidine / analogs & derivatives. Deoxycytidine / history. Deoxycytidine / pharmacology. Deoxycytidine / therapeutic use. Glutamates / history. Glutamates / pharmacology. Glutamates / therapeutic use. Guanine / analogs & derivatives. Guanine / history. Guanine / pharmacology. Guanine / therapeutic use. History, 20th Century. Humans. Indoles / history. Indoles / pharmacology. Indoles / therapeutic use. Pemetrexed. United States

  • Hazardous Substances Data Bank. PEMETREXED .
  • Hazardous Substances Data Bank. GUANINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16143373.001).
  • [ISSN] 0065-2571
  • [Journal-full-title] Advances in enzyme regulation
  • [ISO-abbreviation] Adv. Enzyme Regul.
  • [Language] eng
  • [Publication-type] Historical Article; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Glutamates; 0 / Indoles; 04Q9AIZ7NO / Pemetrexed; 0W860991D6 / Deoxycytidine; 5Z93L87A1R / Guanine; B76N6SBZ8R / gemcitabine; UC96G28EQF / enzastaurin
  •  go-up   go-down


28. Rossi A, Ricciardi S, Maione P, de Marinis F, Gridelli C: Pemetrexed in the treatment of advanced non-squamous lung cancer. Lung Cancer; 2009 Nov;66(2):141-9
Hazardous Substances Data Bank. GUANINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pemetrexed in the treatment of advanced non-squamous lung cancer.
  • Firstly, pemetrexed was approved in combination with cisplatin for the treatment of malignant pleural mesothelioma.
  • Successively, it has been studied, as single-agent, in phase II and III trials for second-line therapy of non-small cell lung cancer (NSCLC).
  • Based on these results, pemetrexed has been registered for the treatment of recurrent NSCLC.
  • The next step was to test pemetrexed plus cisplatin versus gemcitabine plus cisplatin, as first-line therapy in advanced NSCLC patients, in a phase III, non-inferiority, randomized trial.
  • The role of pemetrexed as maintenance therapy after first-line therapy for advanced NSCLC is currently being evaluated into a phase III trial.
  • To date, pemetrexed is registered, at the dose of 500 mg/m(2) on day 1 of a 3-week schedule, in combination with cisplatin, for first-line therapy and, as single-agent, for second-line treatment of patients with non-squamous NSCLC.This review shows the latest and indicates the future developments of pemetrexed in the treatment of advanced NSCLC patients.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Glutamates / therapeutic use. Guanine / analogs & derivatives. Lung Neoplasms / drug therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biological Products / therapeutic use. Cisplatin / therapeutic use. Clinical Trials as Topic. Deoxycytidine / analogs & derivatives. Deoxycytidine / therapeutic use. Folic Acid Antagonists / therapeutic use. Humans. Pemetrexed. Small Cell Lung Carcinoma / drug therapy

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. PEMETREXED .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19577816.001).
  • [ISSN] 1872-8332
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Biological Products; 0 / Folic Acid Antagonists; 0 / Glutamates; 04Q9AIZ7NO / Pemetrexed; 0W860991D6 / Deoxycytidine; 5Z93L87A1R / Guanine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin
  • [Number-of-references] 59
  •  go-up   go-down






Advertisement